#SHRINK NASAL POLYPS FAST CODE#
Patients were randomly allocated, using a computer-generated random code and a block size of 6, to receive 1 of 3 treatments, if eligible, at clinic visit 2: FPANS, 200 µg twice a day (2 actuations to each nostril in the morning and in the evening) beclomethasone dipropionate aqueous nasal spray (BDANS), 200 µg twice a day (2 actuations to each nostril in the morning and in the evening) and placebo (aqueous nasal spray), twice a day (2 actuations to each nostril in the morning and in the evening). The patient group studied was the largest that could be practically assessed in this clinic. This is the first report of a study in this group of patients that we are aware of, and as such, accurate estimations of the parameters required to carry out a meaningful power calculation were not available. This was a randomized, double-blind, placebo-controlled, parallel-group study performed at the Royal National Throat, Nose and Ear Hospital, London, England. Fluticasone has already been shown to be an effective and safe treatment in allergic and nonallergic rhinitis, 10, 11 and results from a preliminary study of patients with moderate to severe polyposis have demonstrated that it is effective in reducing the size of polyps and the associated symptoms of polyposis. The aim of this study was to investigate the effects of fluticasone propionate aqueous nasal spray (FPANS) in controlling the growth of polyps in patients with severe nasal polyposis who were listed for endoscopic surgical treatment. Several studies have demonstrated that topical corticosteroids are effective in reducing the size of polyps, nasal symptoms after surgical treatment, and the recurrence rate of polyps after polypectomy. Although nasal polyposis is histologically an inflammatory disease, 1, 2 the preferred treatment is surgical, but the frequent recurrence of polyps after surgical treatment is a problem for many patients. NASAL POLYPOSIS is a common clinical condition that, despite differing hypotheses of its cause, remains a poorly understood disease. There was some evidence that the group treated with FPANS responded more quickly to intervention and that the magnitude of the response was greater than in the group receiving beclomethasone. No significant difference was observed between the treatment groups in the number of patients requiring polypectomy.Ĭonclusions Fluticasone and beclomethasone aqueous nasal sprays are effective in treating the symptoms of severe nasal polyps. Nasal blockage was significantly decreased in both active groups compared with the group receiving placebo. The percentage change in the mean morning peak nasal inspiratory flow rate was greater in the FPANS-treated group, with a significant effect observed at week 2 ( P=.01). The nasal cavity volume was significantly increased in both the FPANS-treated group and the group receiving beclomethasone compared with placebo ( P≤.01) at the end of treatment. Results The polyp score was significantly decreased in the FPANS-treated group ( P≤.01). Main Outcome Measures Efficacy end points were the need for polypectomy at the end of treatment, the results of acoustic rhinometry, the polyp score, the peak nasal inspiratory flow rate, and an assessment of symptoms.
Patients received 2 actuations to each nostril in the morning and in the evening.
Intervention By random allocation, fluticasone propionate aqueous nasal spray (FPANS), 200 µg twice a day beclomethasone dipropionate aqueous nasal spray, 200 µg twice a day or placebo nasal spray twice a day was administered. Patients Thirty-four patients with severe polyposis listed for endoscopic surgical treatment. Setting A tertiary referral center in London, England. Objectives To investigate the effect of intranasal corticosteroids in the treatment of polyps in patients with severe polyposis listed for surgical treatment and to determine the treatment effect on the progression of the disease.ĭesign A double-blind, randomized, parallel-group, placebo-controlled, 12-week study at a single center. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.
Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.
0 kommentar(er)
